Although treating CIA with flavopiridol, which inhibits CDK1, 2, 4, 6, 7, and 9, has proven to be a successful approach14, we hypothesised that CDK9 is the key target of flavopiridol in the treatment of RA. This evidence concerns the gene CDK1 and rheumatoid arthritis.